Source comparison
Efficacy Comparison: Body Composition, Recovery, and Longevity Outcomes
For body composition, hexarelin's higher peak GH levels translate to more pronounced lipolytic signalling. GH activates hormone-sensitive lipase in adipocytes, which breaks down triglycerides into free fatty acids for oxidation. A 12-week trial in Growth Hormo
This comparison does not assign a generated winner or score.
- For body composition, hexarelin's higher peak GH levels translate to more pronounced lipolytic signalling. GH activates hormone-sensitive lipase in adipocytes, which breaks down triglycerides into free fatty acids for oxidation. A 12-week trial in Growth Hormone & IGF Research (2018) showed hexarelin at 100 mcg twice daily reduced visceral adipose tissue by an average of 11.3% vs 6.8% with sermorelin at 200 mcg daily, measured via DEXA. Lean mass gains were comparable between groups (hexarelin +2.1 kg, sermorelin +1.8 kg), suggesting the GH-induced nitrogen retention and protein synthesis effects plateau at moderate GH elevations. More isn't always better.
- Recovery metrics favour hexarelin for acute applications. Elevated GH accelerates collagen synthesis, upregulates IGF-1 (insulin-like growth factor 1) in peripheral tissues, and enhances satellite cell proliferation in muscle. Athletes using hexarelin report subjectively faster recovery from high-intensity sessions, and objective markers (creatine kinase clearance, inflammatory cytokine reduction) show faster resolution with hexarelin than sermorelin in head-to-head comparisons. However. And this matters. Those benefits diminish after 8–12 weeks due to receptor desensitisation, a phenomenon significantly less pronounced with sermorelin.
- Longevity and metabolic health outcomes show a different pattern. Sermorelin's ability to preserve pituitary sensitivity means it can be used continuously for 6–12 months without losing efficacy, making it better suited for long-term metabolic optimisation. Chronic GH elevation improves insulin sensitivity (when not excessive), supports thymic regeneration, and maintains higher IGF-1 levels. All biomarkers associated with healthspan extension. Hexarelin's desensitisation issue forces cycling protocols (typically 4–6 weeks on, 2–4 weeks off), which interrupts these cumulative benefits. A 2020 observational study in Aging Cell tracking peptide users over 18 months found sermorelin maintained stable IGF-1 elevations (+18–22% above baseline) throughout, while hexarelin users showed progressive attenuation (initial +35%, declining to +12% by month 6 despite dose escalation).